Saxenda 6 mg/ml) Solution for injection
PDF Leaflet Revision Date: 28 January 2026
Clinical Summary
Quick overview from the medicine insert
Indication
Adjunct to diet and exercise for chronic weight management in adults and adolescents with obesity.
Dosage (summary)
Starting dose 0.6 mg daily, titrated to 3.0 mg daily over several weeks.
Special Populations
- Elderly patients
- Renal impairment
- Hepatic impairment
Pregnancy & Breastfeeding
Not recommended during pregnancy or lactation.
Key Drug Interactions
- Insulin and insulin secretagogues
- Warfarin
Contraindications
- Hypersensitivity to liraglutide
- Pregnancy and lactation
Common side effects
- Nausea
- Vomiting
- Diarrhoea
- Headache
- Dizziness
Counselling Points
- Rotate injection sites to avoid amyloidosis.
- Monitor for signs of pancreatitis.
- Stay hydrated to prevent dehydration.
Serious warnings
- Risk of pancreatitis
- Risk of cholelithiasis
- Increased heart rate
Important Disclaimer
The Saxenda 6 mg/ml) Solution for injection professional information leaflet below is the property of Novo Nordisk Pty Ltd and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
